Skip to main content
Figure 3 | SpringerPlus

Figure 3

From: Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade

Figure 3

Comparison of bone-turnover marker levels (mean ± SE). (a) Serum NTX, ICTP, and BAP were assessed in the ZA-treated and control groups at baseline and at 6 and 12 months; (b) Comparison of serum NTX levels, as stratified by baseline T-score (≤0 vs. >0). SE, standard error of the mean; NTX, cross-linked N-telopeptide of type I collagen; ICTP, C-telopeptide of type I collagen; BAP, bone-specific alkaline phosphatase; ZA, zoledronic acid; Ctrl, control.

Back to article page